ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
AZ/Daiichi Sankyo’s datopotamab deruxtecan demonstrates ‘promising’ early results in TNBC
May 11, 2021AstraZeneca (AZ) and Daiichi Sankyo’s antibody drug conjugate (ACD) datopotamab deruxtecan has demonstrated 'promising' preliminary response and disease control in new data evaluating the therapy among patients with metastatic triple negative breast ... -
AZ/Daiichi Sankyo’s antibody drug conjugates prove promising in early trials
January 29, 2021AstraZeneca (AZ) and Daiichi Sankyo have posted new data from Phase I/II trials evaluating their respective antibody drug conjugates (ADCs) Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan.
Pharma Sources Insight January 2025
